New shigella vaccine shows promise in human trial
NCT ID NCT06615375
First seen Jun 27, 2026 · Last updated Jul 17, 2026 · Updated 2 times
Summary
This study tests a new vaccine called Shigella4V2 to see if it can protect people from shigellosis, a severe diarrheal disease. About 120 healthy adults will receive either the vaccine or a placebo and then be exposed to the bacteria in a controlled setting. The goal is to see if the vaccine reduces the number of people who get sick.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SHIGELLOSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio, 45229, United States
-
Hope Clinic of Emory University
Atlanta, Georgia, 30030, United States
-
Johns Hopkins Center for Immunization Research
Baltimore, Maryland, 21205, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.